Local 12, WCPO highlight brain tumor vaccine trial
Local television stations Local 12 and WCPO recently highlighted the Imvax trial that will test a personalized immunotherapy approach designed to work similarly to a vaccine by training the immune system to fight glioblastomas, a deadly brain tumor.
The University of Cincinnati is a study site for the new Phase 2b clinical trial, and Soma Sengupta, MD, PhD, is the site principal investigator.
In the trial, glioblastoma patients will have their tumors removed, and then their tumor cells will be combined with a novel drug to create a personalized vaccine. The combination is then inserted into the patients' abdomens, allowing the immune system to train to fight the tumor cells.
"The patient is making their own antibodies, and their own immune system is working to try and beat this cancer," Sengupta told Local 12.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
‘Designer drug’ shows early neuroprotective signal in acute ischemic stroke
October 28, 2025
Medscape highlighted new trial results led by the University of Cincinnati's Eva Mistry that found an experimental drug shows promise in protecting injured brain cells for patients with acute ischemic stroke.
Is menstrual fluid ‘the most overlooked opportunity’ in women’s health?
October 27, 2025
The Guardian recently reported that period blood has long been thought of as ‘stinky and useless’, but startups are exploring using the fluid to test for a wide range of health conditions — including endometriosis.
What is squalane, and how does it work to moisturize skin?
October 27, 2025
The University of Cincinnati's Kelly Dobos was featured in a Women's Health article discussing squalane, an ingredient being increasingly used in moisturizing skincare products.